ZA200610242B - Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis - Google Patents
Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis Download PDFInfo
- Publication number
- ZA200610242B ZA200610242B ZA200610242A ZA200610242A ZA200610242B ZA 200610242 B ZA200610242 B ZA 200610242B ZA 200610242 A ZA200610242 A ZA 200610242A ZA 200610242 A ZA200610242 A ZA 200610242A ZA 200610242 B ZA200610242 B ZA 200610242B
- Authority
- ZA
- South Africa
- Prior art keywords
- cannabinoids
- combination
- thc
- cannabinoid
- cbd
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 24
- 201000010099 disease Diseases 0.000 title claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 17
- 208000024891 symptom Diseases 0.000 title claims description 9
- 229930003827 cannabinoid Natural products 0.000 claims description 109
- 239000003557 cannabinoid Substances 0.000 claims description 109
- 229940065144 cannabinoids Drugs 0.000 claims description 87
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 67
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 65
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 65
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 65
- 229950011318 cannabidiol Drugs 0.000 claims description 65
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 65
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 65
- 229960004242 dronabinol Drugs 0.000 claims description 58
- 239000003814 drug Substances 0.000 claims description 45
- 241000218236 Cannabis Species 0.000 claims description 39
- 208000002193 Pain Diseases 0.000 claims description 34
- 239000000284 extract Substances 0.000 claims description 32
- 230000036407 pain Effects 0.000 claims description 28
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 206010061218 Inflammation Diseases 0.000 claims description 17
- 230000004054 inflammatory process Effects 0.000 claims description 17
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims description 7
- 241000196324 Embryophyta Species 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 238000009834 vaporization Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 19
- 210000001503 joint Anatomy 0.000 description 19
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000009266 disease activity Effects 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000008859 change Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000003435 antirheumatic agent Substances 0.000 description 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 241000252073 Anguilliformes Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010015943 Eye inflammation Diseases 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010066371 Tendon pain Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940076085 gold Drugs 0.000 description 1
- 210000002478 hand joint Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001584 occupational therapy Methods 0.000 description 1
- 229940058924 other antimalarials in atc Drugs 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0412753A GB2414933B (en) | 2004-06-08 | 2004-06-08 | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200610242B true ZA200610242B (en) | 2008-05-28 |
Family
ID=32696849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200610242A ZA200610242B (en) | 2004-06-08 | 2006-12-06 | Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis |
Country Status (15)
Country | Link |
---|---|
US (3) | US20080139667A1 (hu) |
EP (1) | EP1765314B1 (hu) |
JP (2) | JP4920588B2 (hu) |
KR (1) | KR20070039499A (hu) |
CN (1) | CN1976690B (hu) |
AU (1) | AU2005251505B2 (hu) |
CA (1) | CA2568997C (hu) |
ES (1) | ES2735229T3 (hu) |
GB (1) | GB2414933B (hu) |
HU (1) | HUE046110T2 (hu) |
MX (1) | MXPA06014057A (hu) |
PL (1) | PL1765314T3 (hu) |
PT (1) | PT1765314T (hu) |
WO (1) | WO2005120478A1 (hu) |
ZA (1) | ZA200610242B (hu) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
NZ601567A (en) | 2005-09-29 | 2013-03-28 | Albany Molecular Res Inc | Process for production of delta-9-tetrahydrocannabinol |
GB2432312A (en) * | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB2448535A (en) * | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
US9084771B2 (en) | 2007-05-17 | 2015-07-21 | Sutter West Bay Hospitals | Methods and compositions for treating cancer |
GB2450753B (en) * | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
GB2459637B (en) * | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
PT2280687T (pt) | 2008-03-26 | 2019-06-04 | Stichting Sanammad | Composições de goma de mascar compreendendo canabinóides |
GB2471987B (en) | 2008-06-04 | 2012-02-22 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
EP2424568A1 (en) * | 2009-04-29 | 2012-03-07 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
JP2013520208A (ja) * | 2010-02-24 | 2013-06-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 自己免疫疾患の診断、予後判定、及び処置法 |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
GB2524689B (en) | 2011-05-20 | 2016-01-27 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB2516814B (en) | 2013-06-19 | 2016-08-31 | Otsuka Pharma Co Ltd | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer |
US10016360B1 (en) * | 2013-07-26 | 2018-07-10 | Steven Elbogen | Compositions, uses and methods for making them |
US9333229B2 (en) * | 2013-10-16 | 2016-05-10 | William Bjorncrantz | Winterized crude cannabis extracts and methods of preparation and use |
JP6673895B2 (ja) | 2014-03-21 | 2020-03-25 | エスティー アンド ティー インターナショナル,インコーポレイティド | アサ属抽出方法及び組成物 |
US9186386B2 (en) | 2014-04-17 | 2015-11-17 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
US9044390B1 (en) | 2014-04-17 | 2015-06-02 | Gary J. Speier | Pharmaceutical composition and method of manufacturing |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
FR3022457B1 (fr) * | 2014-06-23 | 2017-09-01 | Assist Publique - Hopitaux De Paris | Utilisation de cannabis pour le traitement de l'achalasie |
US11541003B1 (en) * | 2014-07-28 | 2023-01-03 | Steven Elbogen | Compositions, uses and methods for making them |
CN107205960A (zh) | 2014-10-21 | 2017-09-26 | 联合大麻公司 | 大麻提取物及其制备和使用方法 |
WO2017203529A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
WO2016205923A1 (en) * | 2015-06-25 | 2016-12-29 | Compressed Perforated Puck Technologies Inc. | Ingestible plant source pill and method |
US9827322B2 (en) * | 2015-07-24 | 2017-11-28 | Bao Tran | Medication dispensing system |
SG11201809688RA (en) | 2016-05-04 | 2018-11-29 | Inmed Pharmaceuticals Inc | Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
CN105997985A (zh) * | 2016-06-14 | 2016-10-12 | 云南瑞酚生物科技有限公司 | 一种大麻提取物在制备治疗痛风药物中的应用 |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
AU2017424129B2 (en) * | 2017-07-18 | 2021-12-09 | Deyi Pharmarmaceutical Ltd. | Application of cannabidiol in treatment of pulmonary hypertension |
US11612581B2 (en) | 2017-08-09 | 2023-03-28 | Cannibite Bvba | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects |
CA3072849A1 (en) * | 2017-08-14 | 2019-02-21 | Zynerba Pharmaceuticals, Inc. | Methods of treatment of osteoarthritis with transdermal cannabidiol gel |
CN109498606A (zh) * | 2017-09-15 | 2019-03-22 | 汉义生物科技(北京)有限公司 | 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用 |
WO2019056123A1 (en) * | 2017-09-22 | 2019-03-28 | Inmed Pharmaceuticals Inc. | TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN |
CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
GB201806953D0 (en) * | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
WO2019210401A1 (en) * | 2018-05-01 | 2019-11-07 | Willinsky Michael | Novel anti-inflammatory, analgesic, anti-depressant cannabinoid and methods related to manufacture of same |
WO2019237156A1 (en) * | 2018-06-15 | 2019-12-19 | CannPal Animal Therapeutics Limited | Cannabinoid composition and methods of treatment using the same |
JP2021532171A (ja) * | 2018-07-02 | 2021-11-25 | コンパニオン サイエンシズ リミテッド ライアビリティ カンパニー | カンナビジオールの組み合わせ組成物 |
EP3820452A1 (en) * | 2018-07-09 | 2021-05-19 | Volker Berl | Stabilized formulations of cannabinoid compositions |
WO2020060761A2 (en) * | 2018-09-04 | 2020-03-26 | Skodda Anja | Pet food formulation with cannabinoids |
US11504416B2 (en) * | 2018-09-04 | 2022-11-22 | Paw Power, Inc. | Formulation with cannabinoids |
US11254633B2 (en) | 2018-10-05 | 2022-02-22 | Jonas Alcirdas Navickas | Cannabis thin layer decarboxylation |
CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
JP2022509008A (ja) * | 2018-11-12 | 2022-01-20 | 漢義生物科技(北京)有限公司 | カンナビノイド化合物の神経皮膚炎の治療における応用 |
NL2022614B1 (en) | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical, phyto-cannabinoid based compositions |
NL2022615B1 (en) | 2019-02-21 | 2020-08-31 | Patrick Alexander Unger | Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight |
US20220331406A1 (en) * | 2019-09-30 | 2022-10-20 | Lonza Consumer Health Inc. | Cannabinoid Product for Improving Musculoskeletal Health |
US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
AU2021259495A1 (en) * | 2020-04-20 | 2022-10-27 | Pike Therapeutics, Inc. | Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain |
MX2023001129A (es) | 2020-07-28 | 2023-03-27 | Impello Biosciences Inc | Metodos y composiciones para alterar metabolitos secundarios en plantas. |
JPWO2022085622A1 (hu) | 2020-10-23 | 2022-04-28 | ||
US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
CN112755055B (zh) * | 2020-12-31 | 2022-12-13 | 吉林省农业科学院 | 植物乳杆菌na136与大麻二酚单体联合在制备治疗类风湿性关节炎产品中的应用 |
US12029720B2 (en) | 2021-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
EP4098254A1 (en) * | 2021-06-04 | 2022-12-07 | Assistance Publique, Hopitaux De Paris | Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease |
ES2962999T3 (es) | 2021-07-30 | 2024-03-22 | Cannamedical Pharma Gmbh | Parche transmucoso que comprende un cannabinoide y/o un opiáceo |
WO2024160792A1 (en) | 2023-01-30 | 2024-08-08 | Cannamedical Pharma Gmbh | Improved transmucosal patch comprising a cannabinoid and/or an opioid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100886668B1 (ko) * | 2001-02-14 | 2009-03-04 | 지더블유 파마 리미티드 | 약학적 제제 |
GB2377633A (en) * | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
SI1542657T1 (sl) * | 2002-08-14 | 2012-04-30 | Gw Pharma Ltd | Kanabinoidne kapljevite formulacije za sluzniäśno administracijo |
US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
GB2394894B (en) * | 2002-11-04 | 2005-08-31 | G W Pharma Ltd | New use for pharmaceutical composition |
-
2004
- 2004-06-08 GB GB0412753A patent/GB2414933B/en not_active Expired - Lifetime
-
2005
- 2005-06-07 CA CA2568997A patent/CA2568997C/en active Active
- 2005-06-07 CN CN2005800186476A patent/CN1976690B/zh active Active
- 2005-06-07 JP JP2007526537A patent/JP4920588B2/ja active Active
- 2005-06-07 MX MXPA06014057A patent/MXPA06014057A/es active IP Right Grant
- 2005-06-07 PL PL05749393T patent/PL1765314T3/pl unknown
- 2005-06-07 EP EP05749393.4A patent/EP1765314B1/en active Active
- 2005-06-07 HU HUE05749393A patent/HUE046110T2/hu unknown
- 2005-06-07 AU AU2005251505A patent/AU2005251505B2/en active Active
- 2005-06-07 WO PCT/GB2005/002233 patent/WO2005120478A1/en active Application Filing
- 2005-06-07 ES ES05749393T patent/ES2735229T3/es active Active
- 2005-06-07 PT PT05749393T patent/PT1765314T/pt unknown
- 2005-06-07 KR KR1020067027129A patent/KR20070039499A/ko active Search and Examination
- 2005-06-07 US US11/628,814 patent/US20080139667A1/en not_active Abandoned
-
2006
- 2006-12-06 ZA ZA200610242A patent/ZA200610242B/en unknown
-
2011
- 2011-10-20 JP JP2011230897A patent/JP2012051925A/ja active Pending
-
2016
- 2016-03-14 US US15/068,707 patent/US20160361290A1/en not_active Abandoned
-
2019
- 2019-09-06 US US16/562,515 patent/US20200206184A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06014057A (es) | 2007-03-15 |
HUE046110T2 (hu) | 2020-02-28 |
CA2568997C (en) | 2012-12-04 |
CN1976690A (zh) | 2007-06-06 |
AU2005251505B2 (en) | 2011-03-31 |
AU2005251505A1 (en) | 2005-12-22 |
JP4920588B2 (ja) | 2012-04-18 |
JP2008501770A (ja) | 2008-01-24 |
GB2414933B (en) | 2009-07-15 |
US20160361290A1 (en) | 2016-12-15 |
ES2735229T3 (es) | 2019-12-17 |
GB0412753D0 (en) | 2004-07-07 |
JP2012051925A (ja) | 2012-03-15 |
US20080139667A1 (en) | 2008-06-12 |
CA2568997A1 (en) | 2005-12-22 |
KR20070039499A (ko) | 2007-04-12 |
PT1765314T (pt) | 2019-07-23 |
EP1765314A1 (en) | 2007-03-28 |
CN1976690B (zh) | 2011-05-25 |
EP1765314B1 (en) | 2019-05-01 |
GB2414933A (en) | 2005-12-14 |
WO2005120478A1 (en) | 2005-12-22 |
PL1765314T3 (pl) | 2020-03-31 |
US20200206184A1 (en) | 2020-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200206184A1 (en) | Pharmaceutical compositions for the treatment of disease and/or symptoms in arthritis | |
US7968594B2 (en) | Pharmaceutical compositions for the treatment of pain | |
US20190224140A1 (en) | Cannabinoids for use in the treatment of neuropathic pain | |
EP2182940B1 (en) | Use of tetrahydrocannabinol and/or cannabidiol for the treatment of inflammatory bowel disease | |
WO2007052013A1 (en) | A combination of cannabinoids for the treatment of peripheral neurophatic pain | |
AU2018330807A1 (en) | Compositions comprising a cannabinoid and spilanthol | |
WO2007042811A1 (en) | Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease | |
US20200254038A1 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality | |
KR20230156378A (ko) | 터미날리아 케불라 조성물을 사용한 등통증을 완화시키는 방법 |